NDAORALSOLUTIONPriority Review
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UCEPHAN is an oral solution containing sodium benzoate and sodium phenylacetate, approved in 1987 for hyperammonemia management. It reduces ammonia levels through alternative pathway metabolism, functioning as an adjunctive therapy for urea cycle disorders and hepatic encephalopathy.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand team likely transitioning to defend market share against generics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UCEPHAN offers limited growth trajectory but provides solid experience in mature product management, generic defense strategy, and niche therapeutic expertise in metabolic disorders. Career advancement may require transition to growth-stage products within B. Braun's portfolio.
Brand ManagerProduct Manager
Worked on UCEPHAN at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.